Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas

被引:59
作者
Ray-Coquard, I
Ghesquière, H
Bachelot, T
Borg, C
Biron, P
Sebban, C
LeCesne, A
Chauvin, F
Blay, JY [1 ]
机构
[1] Ctr Leon Berard, F-69373 Lyon, France
[2] Inst Gustave Roussy, Paris, France
[3] Hop Edouard Herriot, Lyon, France
关键词
lymphopenia; treatment-related death; cancer; risk factors; chemotherapy; palliative;
D O I
10.1054/bjoc.2001.2011
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
1-5% of cancer patients treated with cytotoxic chemotherapy die within a month after the administration of chemotherapy. Risk factors for these early deaths (ED) are not well known. The purpose of this study was to establish a risk model for ED after chemotherapy applicable to all tumour types. The model was delineated in a series of 1051 cancer patients receiving a first course of chemotherapy in the Department of Medicine of the Centre Leon Berard (CLB) in 1996 (CLB-1996 cohort), and then validated in a series of patients treated in the same department in 1997 (CLB-1997), in a prospective cohort of patients with aggressive non-Hodgkin's lymphoma (NHL) (CLB-NHL), and in a prospective cohort of patients with metastatic breast cancer (MBC series) receiving first-line chemotherapy. In the CLB-1996 series, 43 patients (4.1%) experienced early. In univariate analysis, age > 60, PS > 1, lymphocyte (ly) count less than or equal to 700 mul(-1) immediately prior to chemotherapy (d1), d1-platelet count less than or equal to 150 GL(-1), and the type of chemotherapy were significantly correlated to the risk of early death (P less than or equal to 0.01). Using logistic regression, PS > 1 (hazard ratio 3.9 (95% CI 2.0-7.5)) and d1-ly count less than or equal to 700 mul(-1) (3.1 (95% CI 1.6-5.8)) were identified as independent risk factors for ED. The calculated probability of ED was 20% (95% CI 10-31) in patients with both risk factors, 6% (95% CI 4-9) for patients with only 1 risk factor, and 1.7% (95% CI 0.9-3) for patients with none of these 2 risk factors. In the CLB-97, CLB-NHL and MBC validation series, the observed incidences of early death in patients with both risk factors were 19%, 25% and 40% respectively and did not differ significantly from those calculated in the model. In conclusion, poor performance status and lymphopenia identify a subgroup of patients at high risk for early death after chemotherapy. (C) 2001 Cancer Research Campaign.
引用
收藏
页码:816 / 822
页数:7
相关论文
共 29 条
[21]   Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape [J].
Restifo, NP .
NATURE MEDICINE, 2000, 6 (05) :493-495
[22]  
RIESCO A, 1970, CANCER, V25, P135, DOI 10.1002/1097-0142(197001)25:1<135::AID-CNCR2820250120>3.0.CO
[23]  
2-9
[24]  
Saito T, 2000, CLIN CANCER RES, V6, P1351
[25]   CAUSES OF DEATH IN FEBRILE GRANULOCYTOPENIC CANCER-PATIENTS RECEIVING EMPIRIC ANTIBIOTIC-THERAPY [J].
SCULIER, JP ;
WEERTS, D ;
KLASTERSKY, J .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1984, 20 (01) :55-60
[26]   A PREDICTIVE MODEL FOR AGGRESSIVE NON-HODGKINS-LYMPHOMA [J].
SHIPP, MA ;
HARRINGTON, DP ;
ANDERSON, JR ;
ARMITAGE, JO ;
BONADONNA, G ;
BRITTINGER, G ;
CABANILLAS, F ;
CANELLOS, GP ;
COIFFIER, B ;
CONNORS, JM ;
COWAN, RA ;
CROWTHER, D ;
DAHLBERG, S ;
ENGELHARD, M ;
FISHER, RI ;
GISSELBRECHT, C ;
HORNING, SJ ;
LEPAGE, E ;
LISTER, TA ;
MEERWALDT, JH ;
MONTSERRAT, E ;
NISSEN, NI ;
OKEN, MM ;
PETERSON, BA ;
TONDINI, C ;
VELASQUEZ, WA ;
YEAP, BY .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (14) :987-994
[27]   Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - A mechanism of immune evasion? [J].
Strand, S ;
Hofmann, WJ ;
Hug, H ;
Muller, M ;
Otto, G ;
Strand, D ;
Mariani, SM ;
Stremmel, W ;
Krammer, PH ;
Galle, PR .
NATURE MEDICINE, 1996, 2 (12) :1361-1366
[28]   Fas ligand in human serum [J].
Tanaka, M ;
Suda, T ;
Haze, K ;
Nakamura, N ;
Sato, K ;
Kimura, F ;
Motoyoshi, K ;
Mizuki, M ;
Tagawa, S ;
Ohga, S ;
Hatake, K ;
Drummond, AH ;
Nagata, S .
NATURE MEDICINE, 1996, 2 (03) :317-322
[29]  
Voorzanger N, 1996, CANCER RES, V56, P5499